Genflow Biosciences plc (GENFF)
- Previous Close
0.0270 - Open
0.0222 - Bid 0.0200 x --
- Ask 0.0614 x --
- Day's Range
0.0222 - 0.0222 - 52 Week Range
0.0149 - 0.0605 - Volume
1,000 - Avg. Volume
1,486 - Market Cap (intraday)
10.558M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
genflowbio.comRecent News: GENFF
View MorePerformance Overview: GENFF
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GENFF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GENFF
View MoreValuation Measures
Market Cap
4.55M
Enterprise Value
4.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--